Specialty Pharmacy

The hydrogel injection has had a lasting drug concentration of 42 days with almost no adverse effects.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Physical symptoms of burnout can include headaches, digestive problems, sleep disturbances, and increased susceptibility to illnesses due to a weakened immune system.

AI is able to quickly analyze, identify, and route data for investigation.

Experts agreed that it was appropriate for patients who use methamphetamine or cocaine to continue opioid use if clinician monitoring was increased and tapering was avoided.

Compared to chemotherapy alone, the combined nivolumab and ipilimumab treatment more than tripled the overall survival rate at 6 years in patients with PD-L1 expression <1%.

The study met its primary endpoint of progression-free survival, and overall survival is continuing to be evaluated.

The CDK12/13 inhibitor will be tested for efficacy and safety in patients with advanced solid tumors, such as breast, ovarian, and Ewing Sarcoma.

A low dose of the combination treatment inhibited AML cell cycle and increased apoptosis.

Investigators must find a different combination or treatment regimen using a dual blockade of the PARP and PI3K/AKT/mTOR pathway.

Patients who received amivantamab plus chemotherapy or amivantamab without chemotherapy presented better outcomes compared to chemotherapy alone.

The importance of findability, accessibility, interoperability, and reusability has become even more significant to academics as government agencies increasingly require data openness and accessibility for funding eligibility.

In addition to overall survival, main efficacy outcomes, such as progression-free survival, objective response rate, and time to response, were compared to chemotherapy alone.

If approved, alectinib would be the only anaplastic lymphoma kinase inhibitor to show reductions in risk of recurrence or death for those with early-stage lung cancer.

Additional research is needed to further evaluate whether adequate emotional support is linked to improvements in health-related quality of life in adults diagnosed with other cancer.

Manufacturers must find the right balance in drug pricing, so that medications are appealing to both public and private insurers while still remaining profitable throughout their lifecycle.

This year's survey features questions focused on compensation, fulfillment, and burnout.

Spatially resolved technology based on next-generation sequencing has the potential to benefit clinical practice and improve the prognosis for cancer patients.

Despite the limited data, prior research indicates there are no serious cannabis-related adverse effects in pediatric patients.

The seamless integration of artificial intelligence and machine learning has the potential to accelerate research and enhance efficiency in a new era of personalized medicine.

Advanced technology can automate many pharmacovigilance tasks to build workflow efficiencies, reduce manual intervention, and free up team members for more strategic activities.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

The drug can now be tested for safety, tolerability, and efficacy in a phase 1 study.

The recent discovery could aid further research on the cause of Huntington’s disease and other inherited conditions.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Generative artificial intelligence is a type of self-learning software that can increase the time pharmacists can allocate to patients, improve medication adherence, and allow patients to access health data on a whim.

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.